Respiratory bacterial infections in cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 3, 2013, Pages 251-258

  Ciofu, Oana ^a,d   Hansen, Christine R ^b   Høiby, Niels ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Department of Clinical Microbiology   (Denmark)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cystic fibrosis; Lung infection; Microbiology; Treatment

Indexed keywords

COTRIMOXAZOLE; FUSIDIC ACID; RIFAMPICIN;

ACHROMOBACTER; BURKHOLDERIA CEPACIA COMPLEX; CYSTIC FIBROSIS; HUMAN; MYCOBACTERIUM; NONHUMAN; PARANASAL SINUS; PATHOGENESIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; LUNG; PARANASAL SINUSES; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTIONS;

EID: 84878113691     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835f1afc     Document Type: Review

References (92)

1. Ulrich M, Beer I, Braitmaier P, et al. Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 2010; 65:978-984.
2. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177:995-1001.
3. Rabin HR, Surette MG. The cystic fibrosis airway microbiome. Curr Opin Pulm Med 2012; 18:622-627.
4. Boucher RC. Human airway ion transport. Part one. Am J Respir Crit Care Med 1994; 150:271-281.
5. Boucher RC. Human airway ion transport. Part two. Am J Respir Crit Care Med 1994; 150:581-593.
6. Muhlebach MS, Miller MB, Moore C, et al. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? Pediatr Pulmonol 2006; 41:445-451.
7. Digoy GP, Dunn JD, Stoner JA, et al. Bacteriology of the paranasal sinuses in pediatric cystic fibrosis patients. Int J Pediatr Otorhinolaryngol 2012; 76:934- 938.
8. Hansen SK, Rau MH, Johansen HK, et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 2012; 6:31-45.
9. Johansen HK, Aanaes K, Pressler T, et al. Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response. J Cyst Fibros 2012; 11:525-531.
10. Hoiby N. Inflammation and infection in cystic fibrosis: hen or egg? Eur Respir J 2001; 17:4-5.
11. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156 (4 Pt 1):1197-1204.
12. Sagel SD, Gibson RL, Emerson J, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154:183-188.
13. Aanaes K, Johansen HK, Poulsen SS, et al. Secretory IgA as a diagnostic tool for Pseudomonas aeruginosa respiratory colonization. J Cyst Fibros 2012; 12:81-87.
14. ECFS Patient Registry Annual Data Report 2008-2009 data. Karup, Denmark: European Cystic Fibrosis Society; 2012.
15. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2010. Bethesda, MD: Cystic Fibrosis Foundation; 2012.
16. UK CF Registry Annual Data Report 2010. Bromley, Kent, UK: Cystic Fibrosis Trust; 2012.
17. Johansen HK, Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992; 47:109-111.
18. de Vrankrijker AM, Wolfs TF, Ciofu O, et al. Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J Med Virol 2009; 81:2096-2103.
19. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004; 23:93-97.
20. Ulrich M, Worlitzsch D, Viglio S, et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros 2010; 9:217-227.
21. Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009; 44:547-558.
22. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9:32.
23. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317-325.
24. Kolpen M, Hansen CR, Bjarnsholt T, et al. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 2010; 65:57-62.
25. Hassett DJ, Korfhagen TR, Irvin RT, et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets 2010; 14:117- 130.
26. Aanaes K, Rickelt LF, Johansen HK, et al. Decreased mucosal oxygen tension in the maxillary sinuses in patients with cystic fibrosis. J Cyst Fibros 2011; 10:114-120.
27. Behrends V, Ryall B, Zlosnik JE, et al. Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections. Environ Microbiol 2012; 15:398-408.
28. Ciofu O, Mandsberg LF, Bjarnsholt T, et al. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 2010; 156 (Pt 4):1108- 1119.
29. Rau MH, Hansen SK, Johansen HK, et al. Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ Microbiol 2010; 12:1643-1658.
30. Pedersen SS, Kharazmi A, Espersen F, Hoiby N. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun 1990; 58:3363-3368.
31. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 1977; 262:1-96.
32. Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992; 47: 6-13.
33. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60:539-574.
34. Ciofu O, Fussing V, Bagge N, et al. Characterization of paired mucoid/nonmucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and Ribo Printing. J Antimicrob Chemother 2001; 48:391-396.
35. Lee B, Schjerling CK, Kirkby N, et al. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. Apmis 2011; 119:263-274.
36. Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251-1254.
37. Hoiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010; 5:1663-1674.
38. Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012; 11:461-479.
39. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969.
40. Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros 2012; 11:293-299.
41. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212-216.
42. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749-1756.
43. Saiman L, Mayer-Hamblett N, Anstead M, et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 2012; 47:641-648.
44. Wilms EB. Azithromycin in cystic fibrosis. Pharmacokinetic and therapeutic aspects of maintenance therapy. PhD thesis, University of Utrecht, Utrecht, The Netherlands. 2012.
45. Mainz JG, Michl R, Pfister W, Beck JF. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation. Am J Respir Crit Care Med 2011; 184:1089-1090.
46. Macdonald KI, Gipsman A, Magit A, et al. Endoscopic sinus surgery in patients with cystic fibrosis: a systematic review and meta-analysis of pulmonary function. Rhinology 2012; 50:360-369.
47. Vital D, Hofer M, Benden C, et al. Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients. Respiration 2012. doi:10.1159/000339627. [Epub ahead of print]
48. Mainz JG, Hentschel J, Schien C, et al. Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation. J Cyst Fibros 2012; 11:158-161.
49. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev 2012; 11:CD009528.
50. Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010; 202:1585-1592.
51. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008; 68:223-240.
52. Hengzhuang W, Wu H, Ciofu O, et al. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2011; 55:4469-4474.
53. Hengzhuang W, Wu H, Ciofu O, et al. In vivo pharmacokinetics/ pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 2012; 56:2683-2690.
54. Hengzhuang W, Ciofu O, Yang L, et al. High beta-lactamase levels change the pharmacodynamics of beta-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2012; 57:196-204.
55. Mainz JG, Naehrlich L, Schien M, et al. Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax 2009; 64:535-540.
56. Branger C, Gardye C, Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiol 1996; 45:294-301.
57. Goerke C, Wolz C. Adaptation of Staphylococcus aureus to the cystic fibrosis lung. Int J Med Microbiol 2010; 300:520-525.
58. Molina A, Del CR, Maiz L, et al. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J Antimicrob Chemother 2008; 62:961-967.
59. Vanderhelst E, De ML, Verbanck S, et al. Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients. J Cyst Fibros 2012; 11:2-7.
60. Goss CH, Muhlebach MS. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 2011; 10:298-306.
61. Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3:67-91.
62. Quon BS, Reid JD, Wong P, et al. Burkholderia gladioli - a predictor of poor outcome in cystic fibrosis patients who receive lung transplants? A case of locally invasive rhinosinusitis and persistent bacteremia in a 36-year-old lung transplant recipient with cystic fibrosis. Can Respir J 2011; 18:e64-e65.
63. Medina-Pascual MJ, Valdezate S, Villalon P, et al. Identification, molecular characterisation and antimicrobial susceptibility of genomovars of the Burkholderia cepacia complex in Spain. Eur J Clin Microbiol Infect Dis 2012; 31:3385-3396.
64. Gilchrist FJ, Webb AK, Bright-Thomas RJ, Jones AM. Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids. J Cyst Fibros 2012; 11:458-460.
65. Uluer AZ, Waltz DA, Kalish LA, et al. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros 2013; 12:54-59.
66. Schmerk CL, Valvano M. Burkholderia multivorans survival and trafficking within macrophages. J Med Microbiol 2012; 62 (Pt 2):173-184.
67. Kopp BT, Abdulrahman BA, Khweek AA, et al. Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from cystic fibrosis patients. Biochem Biophys Res Commun 2012; 424:221-227.
68. Hansen CR, Pressler T, Nielsen KG, et al. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 2010; 9:51-58.
69. Ridderberg W, Wang M, Norskov-Lauritsen N. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J Clin Microbiol 2012; 50:2688-2694.
70. Spilker T, Vandamme P, LiPuma JJ. Identification and distribution of Achromobacter species in cystic fibrosis, J Cyst Fibros 2012. doi:10.1016/j.jcf.2012.10.002. [Epub ahead of print]
71. Lambiase A, Catania MR, Del PM, et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2011; 30:973-980.
72. Pereira RH, Carvalho-Assef AP, Albano RM, et al. Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients. J Clin Microbiol 2011; 49:3649-3651.
73. Amoureux L, Bador J, Siebor E, et al. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: First French data. J Cyst Fibros 2012. http://dx.doi.org/10.1016/j.jcf.2012.08. 005
74. Ridderberg W, Bendstrup KE, Olesen HV, et al. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros 2011; 10:466-469.
75. Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998; 27:158- 163.
76. Bador J, Amoureux L, Duez JM, et al. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob Agents Chemother 2011; 55:4912-4914.
77. Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011; 183:635-640.
78. Waters V, Atenafu EG, Salazar JG, et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 2012; 11:8-13.
79. Dalboge CS, Hansen CR, Pressler T, et al. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J Cyst Fibros 2011; 10:318-325.
80. Verregghen M, Heijerman HG, Reijers M, et al. Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case-control study. J Cyst Fibros 2012; 11:340-343.
81. Ritz N, Ammann RA, Casaulta AC, et al. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. Eur J Pediatr 2005; 164:577-582.
82. Pompilio A, Pomponio S, Crocetta V, et al. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiol 2011; 11:159.
83. Hansen CR. Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen. Curr Opin Pulm Med 2012; 18:628-631.
84. Goncalves-Vidigal P, Grosse-Onnebrink J, Mellies U, et al. Stenotrophomonas maltophilia in cystic fibrosis: improved detection by the use of selective agar and evaluation of antimicrobial resistance. J Cyst Fibros 2011; 10:422- 427.
85. Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo- outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998; 52:453-490.
86. Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185:231-232.
87. Hill UG, Floto RA, Haworth CS. Nontuberculous mycobacteria in cystic fibrosis. J R Soc Med 2012; 105 (Suppl 2):S14-S18. An extensive and exhaustive review of the role of NTM in CF.
88. Catherinot E, Roux AL, Vibet MA, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros 2013; 12:74-80.
89. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554-3563.
90. Catherinot E, Roux AL, Vibet MA, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2012. doi: 10.1183/09031936.00065612. [Epub ahead of print]
91. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 24 (Suppl 5):S6-S52.
92. Yang L, Jelsbak L, Marvig RL, et al. Evolutionary dynamics of bacteria in a human host environment. Proc Natl Acad Sci U S A 2011; 108:7481- 7486.